Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis—a randomized controlled trial (PSORRO)

Mette Gyldenløve,Howraman Meteran,Jennifer A. Sørensen,Simon Fage,Yiqiu Yao,Jesper Lindhardsen,Christoffer V. Nissen,Tanja Todberg,Simon F. Thomsen,Lone Skov,Claus Zachariae,Lars Iversen,Mia-Louise Nielsen,Alexander Egeberg

The Lancet Regional Health - Europe（2023）

引用 1|浏览18

暂无评分

摘要

Financial support was received from Herlev and Gentofte Hospital, University of Copenhagen, and independent grants from private foundations in Denmark. No pharmaceutical company, including the market authorization holder of roflumilast, was involved in the study at any point.

查看译文

关键词

Psoriasis, Roflumilast, PDE4-inhibitor, Phosphodiesterase-4, Therapy, Chronic obstructive pulmonary disease, COPD

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要